Breaking News, Financial News

Financial Report: Lilly

Recognizes worldwide revenue of $871.2 million in the quarter for bamlanivimab COVID-19 treatment.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly 4Q Revenues: $7.4 billion (+22%) 4Q Earnings: $2.1 billion (+42%) YTD Revenues: $24.5 billion (+10%) YTD Earnings: $6.2 billion (-26%) Comments: The company recognized worldwide revenue of $871.2 million in the quarter for bamlanivimab. Excluding bamlanivimab revenue, worldwide revenue grew by 7%. Key growth products launched since 2014, consisting of Trulicity, Verzenio, Taltz, Tyvyt, Olumiant, Jardiance, Emgality, Cyramza, Retevmo, Baqsimi and Basaglarcontributed nearly 12 percentag...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters